bendamustine hydrochloride has been researched along with Antiphospholipid Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Z; Mandernach, MW; Markham, M | 1 |
| Ames, PR; Gentile, F; Merashli, M | 1 |
| Frickhofen, N; Hackenberg, U; Josten, KM; Jung, B; Kirchmaier, CM; Manner, H; Plum, N; Tonassi, L | 1 |
3 other study(ies) available for bendamustine hydrochloride and Antiphospholipid Syndrome
| Article | Year |
|---|---|
Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
Topics: Antibodies, Antiphospholipid; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antiphospholipid Syndrome; Bendamustine Hydrochloride; Diagnosis, Differential; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Rare Diseases; Rituximab; Treatment Outcome | 2019 |
Rituximab/Bendamustine treatment of chronic lymphatic leukemia leads to sustained remission of antiphospholipid antibodies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiphospholipid Syndrome; Bendamustine Hydrochloride; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab | 2019 |
Successful treatment of catastrophic antiphospholipid antibody syndrome (CAPS) associated with splenic marginal-zone lymphoma with low-molecular weight heparin, rituximab and bendamustine.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Antineoplastic Agents; Antiphospholipid Syndrome; Bendamustine Hydrochloride; Female; Heparin, Low-Molecular-Weight; Humans; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Rituximab; Splenic Neoplasms | 2008 |